Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially the first FDA-approved blood test. However, experts are unsure whether these will be as ...

Offering a blood test as a secondary option in individuals who previously declined colonoscopy or FIT increased CRC screening by 7.5%. There was no decrease in uptake of first-line screening options.

Novel first-generation cell-free DNA blood (cf-bDNA) tests for colorectal cancer (CRC) cost more and are less effective than colonoscopy or stool tests, a new analysis suggests. Researchers estimated ...

ACG posed several key questions and developed practical recommendations for practice providers. The recommendations were crafted through a focused literature search and supplemented by existing ...

MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most ...

In a comparison against multiple alternative screening strategies, a cell-free DNA blood test (cf-bDNA) prevented the fewest cancers and cancer-specific deaths versus no screening. With an estimated ...

The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. The FDA’s approval was based on findings ...

Blood-based liquid biopsy tests for colorectal cancer (CRC) are in development and may soon hit the market, expanding potential options for patients who refuse traditional colonoscopy. But would they ...

WASHINGTON -- A blood-based test for the early detection of colorectal cancer (CRC) met its prespecified sensitivity and specificity endpoints, according to results from the PREEMPT CRC study. Using ...

PALO ALTO, Calif., November 05, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical ...

Mailing mt-sDNA tests to Medicare Advantage enrollees improved CRC screening adherence, with a 49.4% overall adherence rate. Digital outreach, especially combining email and text, significantly ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based ...